Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 50 people enrolled
- Started
- 22 Mar 2021
- Ended
- 8 Sept 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- EndoPAT
- Blood Pressure Cuff
- Echocardiogram
- Quality of Life Assessment
- Blood Tests
- Record updated
- 4 March 2026
- Why it stopped
- Study terminated by PI
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age ≥ 18
- Confirmed diagnosis of multiple myeloma
- Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt of 1-3 previous lines of therapy and with a 2-week washout from prior therapy
- Receiving carfilzomib as either standard-of-care therapy or as part of a clinical trial
Who cannot take part
- Previous receipt of anthracycline chemotherapy
- Previous receipt of carfilzomib
- Four or more previous lines of therapy
- Active pregnancy at the time of enrollment
Where in United States
- University of ChicagoChicago, United States
About the trial
What the trial wants to find out
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.
The 2 groups in the trial
- Participants with Normal Baseline Endothelial Function
Treatment: EndoPAT, Blood Pressure Cuff, Echocardiogram, Quality of Life Assessment, and Blood Tests
- Participants with Abnormal Baseline Endothelial Function
Treatment: EndoPAT, Blood Pressure Cuff, Echocardiogram, Quality of Life Assessment, and Blood Tests
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Risk Factors for Dyspnea and Cardiotoxicity in Patients With Multiple Myeloma Who Receive Carfilzomib: A Prospective Pilot Study
- Record updated
- 4 March 2026